Abstract
The translation of genes encoded in the mitochondrial genome requires specific machinery that functions in the organelle. Among the many mutations linked to human disease that affect mitochondrial translation, several are localized to nuclear genes coding for mitochondrial aminoacyl-transfer RNA synthetases. The molecular significance of these mutations is poorly understood, but it is expected to be similar to that of the mutations affecting mitochondrial transfer RNAs. To better understand the molecular features of diseases caused by these mutations, and to improve their diagnosis and therapeutics, we have constructed a Drosophila melanogaster model disrupting the mitochondrial seryl-tRNA synthetase by RNA interference. At the molecular level, the knockdown generates a reduction in transfer RNA serylation, which correlates with the severity of the phenotype observed. The silencing compromises viability, longevity, motility and tissue development. At the cellular level, the knockdown alters mitochondrial morphology, biogenesis and function, and induces lactic acidosis and reactive oxygen species accumulation. We report that administration of antioxidant compounds has a palliative effect of some of these phenotypes. In conclusion, the fly model generated in this work reproduces typical characteristics of pathologies caused by mutations in the mitochondrial aminoacylation system, and can be useful to assess therapeutic approaches.
INTRODUCTION
Aminoacyl-tRNA synthetases (aaRSs) constitute an ancient family of enzymes that catalyze the attachment of amino acids onto their cognate transfer RNAs (tRNAs). The enzymes carry out a two-step reaction that first condenses the amino acid with ATP to form the aminoacyl adenylate and then transfer the aminoacyl moiety to the tRNA 3′ end (1). The aminoacyl-tRNA is then delivered to the ribosome by elongation factors for the decoding of the messenger RNA (mRNA) according to genetic code rules. In animals, as in the vast majority of eukaryotes, protein synthesis occurs simultaneously in the cytoplasm and some organelles that possess their own genome. Human mitochondria have a circular double-stranded DNA genome (mtDNA) that codes for 13 polypeptides that are components of the respiratory chain and the oxidative phosphorylation (OXPHOS), responsible for supplying energy to the cell. Additionally, human mtDNA codes for two ribosomal RNAs and the 22 mitochondrial tRNAs (mt-tRNAs) required to decode all human mitochondrial mRNA codons. To aminoacylate these 22 tRNAs, a whole set of nuclear-encoded aaRS needs to be imported and function inside the organelle.
Defects in elements involved in mitochondrial protein synthesis are related to a heterogeneous number of mitochondrial diseases, which show diverse clinical symptoms including deafness, blindness, encephalopathy and myopathy. More than 50% of the known mtDNA mutations are concentrated in tRNA genes and associated to a wide variety of ailments (2). For example, mutations in mt-tRNALeu (UAA) gene cause mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS) (3,4), in mt-tRNALys produce myoclonic epilepsy with ragged red fibers (MERRF) (5) and in tRNASer typically lead to deafness (6). A poor understanding of the pathophysiology of mitochondrial translation diseases, the wide variety of symptoms they cause and the technical difficulty of working with mutant mitochondria complicate the research on these disorders. For that reason, the construction of model systems is necessary to facilitate the characterization, diagnosis and development of therapeutic approaches.
Possibly due to their essential role, mutations in aaRS are only described in rare diseases with low prevalence (7). Some types of the inherited peripheral neuropathy Charcot-Marie Tooth (CMT) and distal spinal muscular atrophy type V have been related to mutations in the genes coding for the cytoplasmic glycyl-, tyrosyl-, alanyl- and lysyl-tRNA synthetases (8–11). The pathogenic mechanisms for these disorders are not clear. In some cases a loss of aminoacylation activity and, in others, a toxic gain of function, have been proposed as the reasons behind the pathogenicity of these mutations (12–14). More recently, pathogenic mutations in nuclear-encoded proteins of the mitochondrial translation apparatus have also been described [reviewed in (7)], including mutations in aspartyl-, arginyl-, tyrosyl-, seryl-, histidyl-, alanyl-, methionyl-, glutamyl- and phenylalanyl-tRNA synthetases (15–23).
Some animal models for neurological conditions caused by mutations in cytoplasmic aaRS have been generated. For example, mice and Drosophila melanogaster have been used as models to study the CMT symptoms caused by substitutions in the glycyl-tRNA synthetase gene (GARS) (24–26) and tyrosyl-tRNA synthetase gene (YARS) (27). Similarly, the sequence identity between some human and Saccharomyces cerevisiae mt-tRNAs (28,29) has allowed the generation of yeast strains with mutations in mt-tRNA that mimic some human neuropathies such as MELAS (30). Trans-mitochondrial cybrid cell lines (31) have also been used to study the biochemical and cellular consequences of point mutations and deletions of mtDNA, including those affecting tRNA genes (32). A few animal models for mitochondrial illnesses caused by mutations in nuclear-encoded components of mitochondrial gene translation exist, such as the D. melanogaster technical knockout (tko) that carries a point mutation in the MRPS12 nuclear gene encoding mitochondrial ribosomal protein S12 (33). Finally, allotropic expression of functional tRNA derivatives in cybrid cells holding MERRF or MELAS mutations (34–37), as well as overexpression of mitochondrial aaRS (38,39), have been tested as therapeutic approaches. Blastocyst injection of ES cell cybrids has allowed the creation of heteroplasmic trans-mitochondrial mice bearing mutant mtDNA from donor cells (40–43).
The aim of the present work is the development of a D. melanogaster model to study the cellular and molecular effects of a deficient mt-tRNA aminoacylation activity. To achieve this goal, and avoid the drawbacks of manipulating mtDNA-encoded tRNAs, we have decided to limit the function of a nuclear-encoded mitochondrial aaRS, seryl-tRNA synthetase 2 (DmSRS2) (Figure 1), by means of an RNA interference (RNAi) approach. We have previously reported the identification of SRS2 in D. melanogaster, and its preliminary comparison with a paralogous protein present in insects (SLIMP) (44). >
Here we describe the generation of a D. melanogaster model for human mitochondrial disease caused by mitochondrial aminoacylation restriction. The model has been first characterized at the molecular level, showing a decrease in DmSRS2 expression and function, with a reduction in mt-tRNASer aminoacylation. Secondly, the effect of DmSRS2 general or tissue-restricted depletion has been analyzed. This insult compromises viability, longevity, motility and tissue development. At the cellular level, SRS2 silencing strongly affects mitochondrial morphology, biogenesis and function, and induces lactic acidosis and reactive oxygen species (ROS) accumulation. The later observation prompted us to investigate the effect of administering antioxidant molecules to the affected animals. We report that such a treatment has a palliative effect and reduces the severity of some of the phenotypes caused by the silencing of the enzyme.
MATERIALS AND METHODS
Fly maintenance and strains
Flies were maintained in 60% relative humidity in 12 h light/dark cycles at 18, 25 or 29°C depending on the experiment. Flies were fed with standard fly food except when testing the effect of antioxidant molecules in the phenotype. In these cases, the micronutrient supplement K-PAX (K-PAX Inc.) was added to fly’s food at a final concentration of 6.9 mg/ml. To determine the chromosomal location of the UAS-RNAi transgenes and for the proper manipulation of the transgenic flies, the balancer line w; If/CyO; Ly/TM3-Sb was used. UAS and GAL4 lines used in this study were as follows: w; UAS-dicer-2, yw; actin5C-GAL4/TM6B, w; patched-GAL4, w; repo-GAL4/TM6B, yw; Mef2-GAL4, and the yw; nubbin-GAL4; UAS-dicer-2/CyO-TM6B that ensures co-segregation of nubbin-GAL4 with UAS-dcr2.
Generation of transgenic UAS-RNAi strains
A 543 bp fragment from the DmSRS2 cDNA was subcloned into pWIZ vector in an inverted repeat manner (45). Transgenic fly lines were obtained by microinjection of the construction into w1118 embryos using standard procedures (46). One homozygous strain was obtained carrying the UAS-RNAiDmSRS2 transgene in chromosome II, which on crossing gave rise to the w; RNAiDmSRS2 strain 1-dcr2 homozygous strain, that expressed both the RNAiDmSRS2 and dicer-2 protein. In addition, an independent strain carrying a different UAS-RNAiDmSRS2 transgene in chromosome II (RNAiDmSRS2 strain 23003) and a line used to silence the respiratory chain subunit ND75 from complex I (RNAiND75), were purchased from the VDRC stock centre (ID 23003 and 100733, respectively) (47). Induction of RNAi transgene expression was based on the UAS-GAL4 system (48).
Viability and life span determinations
To measure adult viability, crosses with the heterozygous actin5C-GAL4 driver were maintained at 25 and 29°C and progeny was counted to n > 150. The dsRNA was expected to be expressed in 50% of the progeny, while the remaining 50% should not produce it and was used as internal negative control. Adults with active RNAiDmSRS2 were counted and represented relative to the maximum expected viability, set as 100%. For life span experiments, crosses with repo-GAL4 driver were kept at 29°C and with Mef2-GAL4 driver at 18°C until adulthood to allow viability. For each experiment, ≥100 adults were collected, transferred to fresh food vials every two days, maintained at 29°C and counted daily. Survival curves were constructed and compared using the Log-rank (Mantel-Cox) method.
Climbing assays
8–14 control flies (Mef2-GAL4), Mef2-GAL4; RNAiDmSRS2 strain 1-dcr2 or RNAiDmSRS2 strain 23003 flies, hatched at 18°C, were collected in food vials at 29°C for 24 h. Climbing assays were performed as described (49), setting horizontal marks at 20, 50 and 100 mm height and giving flies 60 s to climb the vial.
Quantitative real-time polymerase chain reaction
Total RNA was extracted from third instar larvae with TRIzol (Invitrogen), digested with DNase I and cleaned with the RNeasy MinElute Cleanup kit (Qiagen). One microgram of total RNA was retrotranscribed into cDNA using oligo(dT) primers to perform quantitative real-time polymerase chain reactions (PCRs) by means of Power SYBR Green and a StepOnePlus Real-time PCR System (Applied Biosystems). cDNA templates were amplified with a pair of primers designed with the Primer Express® software (Applied Biosystems) to detect the DmSRS2 cDNA (5′CCGTTCTGCGACCATTCAT3′ and 5′CAGCTTCGTCTCCGGTATCC3′) and another to detect the Rp49 cDNA, used as endogenous control (5′TGCCCACCGGATTCAAGA3′ and 5′AAACGCGGTTCTGCATGAG3′). Standard curves were calculated for both primer pairs to ensure a high efficiency level. Twenty microliters of reactions were prepared following the manufacturer’s instructions, using ROX as reference dye and the following conditions: 50°C for 2 min; 95°C for 10 min; 40 cycles (95°C for 15 s; 60°C for 1 min). Fold expression changes were calculated using the 2−ΔΔCT method, where ΔΔCT is the RNAi ΔCT [CT average for DmSRS2 − CT average for the reference gene (Rp49)] − the w1118 control ΔCT [CT average for DmSRS2 − CT average for the reference gene (Rp49)]. The value obtained for control larvae is represented as 1 and the other values are represented relative to it.
Analysis of in vivo mt-tRNASer aminoacylation
Total RNA was extracted with TRIzol (Invitrogen) from third instar larvae with inactive or active RNAiDmSRS2 and 30 μg of total RNA were electrophoresed on high-resolution acid gels, as described in (50) and transferred to a Hybond XL (GE Healthcare) membrane by vacuum gel drying transfer (51). Aminoacylated mt-tRNAs were analyzed by northern blot using the following radiolabeled probes: 5′TGGTCATTAGAAGTAAGTGCTAATTTAC3′ for mt-tRNALys (CUU), used as a control, 5′TGGAGAAATATAAATGGAATTTAACC3′ for mt-tRNASer (GCU) and 5′TGGAAGTTAATAGAAAATTAAATTCTATCTTATG3′ for mt-tRNASer (UGA). Signals were digitalized using a PhosphorImager™ from a gel exposed storage phosphor screen and were quantified using the ImageQuant™ TL software (GE Healthcare).
Wing preparation and microscopy image analyses
Twelve or more adults were kept at room temperature in 75% ethanol, 25% glycerol for >24 h and wings were excised in cold phosphate buffered saline (PBS) and mounted in Fauré’s medium. Images were taken in a Nikon E600 microscope with an Olympus DP72 camera, and L3-L4 areas were measured from males and females separately with the ImageJ software (52). Images from whole flies were taken at 30× with a MZ 16F Leica stereomicroscope equipped with a DFC 300FX camera.
Electron microscopy
Fat bodies from 8 to 10 third instar larvae were dissected in Schneider’s medium and fixed in 2% glutaraldehyde in 0.1 M cacodylate buffer pH 7.2. Postfixation was done with 2% OsO4 and 1.6% K3Fe(CN)6 in cacodylate buffer. Sections were contrasted with uranyl acetate and visualized in a Jeol JEM 1010 electron microscope with a high-resolution digital camera. For mitochondrial surface determination, >70 mitochondria were measured, and for mitochondrial density calculation, 35 images at 20 000× were analyzed for each sample. The surface occupied by glycogen was calculated taking >15 images at 20 000× for each sample, and it was represented as the area covered by glycogen in μm2 in 100 μm2 of total area (subtracting the mitochondrial and lipid droplet surface). Image analyses were performed with the ImageJ software (52).
mtDNA copy number determination
mtDNA was quantified as described (44).
Lactate, glycogen and pH determination
Concentration of lactate in larval tissues was measured as described (53) with a Cobas Mira Plus analyzer (Roche). Concentration of glycogen in larval tissues was measured adapting the protocol described (54) to a Safire 2 fluorometer (Tecan Group Ltd.). For both experiments, 20 larvae were used for each determination, and results were normalized by total protein, measured using BCA Protein Assay Kit (Pierce). pH of larval homogenates was measured at 4°C with a pH meter GLP21 (Crison).
Oxygen consumption measurements
Oxygen consumption was measured with an Oxygraph-2 k (Oroboros) as described (44). Complex I respiratory control ratios (RCR) were calculated using the oxygen consumption in the presence and absence of ADP (GMD and GM). The oxygen flux values in different respiratory states were normalized dividing them by the mitochondrial rate calculated from the relative mtDNA quantification (55) considering the rate for control larvae as 1 and representing the other values relative to it.
ROS assays
Wing imaginal discs were incubated with dihydroethidium (Invitrogen), rinsed twice in Schneider’s medium, fixed with 4% P-paraformaldehyde and washed with PBS (56). Superoxide anion accumulation was visualized by confocal imaging.
Statistical analyses
All the statistical analysis were performed using the software GraphPad Prism version 5.00, except the two-way analysis of variance (ANOVA) test that was performed with the SPSS 15.0 software.
RESULTS
DmSRS2 knockdown causes an aminoacylation deficiency
To partially reduce the levels of the D. melanogaster SRS2 in an inducible and regulated manner, we used RNAi expression under the control of the UAS-GAL4 system. We used two fly strains holding two RNAi transgenes designed to specifically target two different regions of the DmSRS2 mRNA (RNAiDmSRS2 strain 1-dcr2 and RNAiDmSRS2 strain 23003). When the RNAiDmSRS2 strains were crossed with the actin5C-GAL4 driver, the expression of the RNAi transgenes was constitutively and ubiquitously induced in the offspring. Because GAL4 activity is temperature dependent, crosses with actin5C-GAL4 were maintained at the highest temperature that allowed viability of the progeny, to ensure high efficiency of the RNAi silencing. Thus, the cross with RNAiDmSRS2 strain 1-dcr2 was maintained at 29°C, while the one with RNAiDmSRS2 strain 23003 was kept at 25°C. Both RNAi transgenes produced a reduction in DmSRS2 mRNA levels in larvae (Figure 2A), with different efficiencies depending on the strain used: RNAiDmSRS2 strain 1-dcr2 showed a mild effect with limited reduction to 0.796 ± 0.040, and RNAiDmSRS2 strain 23003 displayed a strong effect with a marked decrease to 0.163 ± 0.001, while the mRNA levels of the cytosolic DmSRS (DmSRS1) and the DmSRS2 paralogous SLIMP did not change significantly (Supplementary Figure S1). The availability of two strains with different efficiencies to silence DmSRS2 allowed us to investigate the range of phenotypes resulting from different degrees of silencing. This is reminiscent of the different severity levels and variety of symptoms that occur in most mitochondrial diseases. >
To prove that the RNAiDmSRS2 was decreasing the function of the enzyme, the relative levels of aminoacylated and deacylated mitochondrial tRNASer (mt-tRNASer) from larvae were analyzed by northern blot (Figure 2B), and the levels of in vivo aminoacylation under general RNAi induction were quantified and compared with RNAi inactive larvae (Figure 2C).
In Figure 2B, intensity of the upper bands (corresponding to aminoacylated tRNAs) for the two mt-tRNASer isoacceptors (GCU and UGA) was reduced when RNAi was functional (+), while mt-tRNALys (CUU) was maintained completely aminoacylated, showing a single band (Supplementary Figure S2). RNAiDmSRS2 (+) larvae from strain 1-dcr2 showed a moderate decrease (Figure 2C) in mt-tRNASer (GCU) aminoacylation level to 82.10 ± 0.01%, while larvae from strain 23003 showed a strong reduction to 50.44 ± 3.31%. Levels of mt-tRNASer (UGA) aminoacylation were similar in both strains when RNAi was functional: 37.88 ± 5.3% (strain 1-dcr2) and 38.06 ± 4.14% (strain 23003). Indeed, we observed a reduction of the mitochondrial encoded proteins ND1 (MT-ND1) and COX2 (MT-CO2) in knockdown larvae from RNAiDmSRS2 strain 1-dcr2 at 29°C (5.2% and 43.6%, respectively) and strain 23003 at 25°C (48.7 and 51.3%, respectively) compared with the control w1118 (Supplementary Figure S3). These results confirmed that DmSRS2 was the D. melanogaster mitochondrial seryl-tRNA synthetase, as its silencing specifically diminished the amount of seryl-mt-tRNASer and mitochondrially encoded proteins. Therefore, the RNAi of DmSRS2 was confirmed to be a useful approach to limit the mitochondrial translation capacity in a controlled manner.
DmSRS2 silencing influences viability and tissue development
To study the phenotype caused by DmSRS2 depletion, we crossed the actin5C-GAL4 driver with the two transgenic RNAiDmSRS2 strains. At 25°C, 21.8% of strain 1-dcr2 pupae, and 1.4% of strain 23003 pupae, hatched successfully. At 29°C, temperature at which GAL4 activity is maximum (57), no adult animals could be observed to hatch from pupae (Figure 3A). As expected for an aaRS, silencing of DmSRS2 impedes viability. >
We used tissue-restricted RNAi induction to investigate effects caused by DmSRS2 silencing without compromising the viability of the organisms (Figure 3B and C). To express the RNAi in the wing imaginal disc region, which afterward develops into the adult wing blade and hinge, we crossed the RNAiDmSRS2 strains with nubbin-GAL4; UAS-dcr2 driver (Figure 3B). As shown in the right panel, a 32.3% (25°C) and a 97.7% (29°C) of RNAiDmSRS2 strain 1-dcr2 flies showed tissue damage in wings, while all the RNAiDmSRS2 strain 23003-dcr2 flies presented wing defects both at 25 and 29°C. Although the wings conserved their general structure, the blade was unable to unfold and develop completely (left panel).
To analyze the cellular effects of DmSRS2 silencing in the wing, we crossed the RNAi transgenic lines with patched-GAL4 driver at 29°C, which allows for a better definition of the RNAi expressing region (Figure 3C). The gene patched is expressed in the anteroposterior border of the wing disc, which gives rise to the wing area limited by longitudinal veins 3 (L3) and 4 (L4) (58). A partial or total loss of the anterior cross vein (acv) was observed in 4 and 15% of the wings from flies emerging from the crosses with strain 1-dcr2 and strain 23003, respectively. Moreover, in these animals, the L3-L4 wing area underwent a significant narrowing of 88.58 ± 2.13% (strain 1-dcr2) and 80.83 ± 2.54% (strain 23003), compared with the parental strain (patched-GAL4). The reduction in L3-L4 area was not due to a decrease in cell size, but in cell number, although there was no evidence of apoptosis when wing imaginal discs were subjected to Caspase-3 immunofluorescence (data not shown). Because the L2-L3 area, contiguous to L3-L4, did not show a significant decrease (data not shown), the effect observed in the L3-L4 region was considered cell autonomous.
Life span and motility are reduced by DmSRS2 knockdown
With the purpose of disrupting Drosophila mitochondrial translation in tissues typically affected in patients with mitochondrial pathologies, DmSRS2 silencing was restricted to neural and muscle cell types using repo-GAL4 and Mef2-GAL4 drivers, respectively (Figure 4). In Figure 4A, the survival curve for RNAiDmSRS2 strain 1-dcr2 flies with a repo-GAL4 driver at 29°C was significantly different to the parental line repo-GAL4, with a reduction in half-life from 32 to 21 days. Furthermore, repo-GAL4; RNAiDmSRS2 strain 23003 individuals were unable to hatch from pupal stage, at any tested temperature (18, 25 and 29°C). >
To obtain adult animals from the Mef2-GAL4 × RNAiDmSRS2 strain 1-dcr2 and the Mef2-GAL4 × RNAiDmSRS2 strain 23003 crosses, progeny was maintained at 18°C and adult life span was compared with control line Mef2-GAL4. Muscle-restricted DmSRS2 silencing led to a shortening in life span with half-life of 6 days, compared with 22 days of the control (Figure 4B). The RNAiDmSRS2 induction in muscle dramatically affected adult locomotion capacity when compared with parental strain Mef2-GAL4. In standard climbing assays, flies from the parental line showed 100% at 20 mm, 98.38 ± 0.70% at 50 mm and 95.59 ± 0.98% at 100 mm, RNAiDmSRS2 strain 1-dcr2 flies showed a decrease to 87.90 ± 4.79% at 20 mm, 75.22 ± 2.88% at 50 mm, 60.27 ± 4.70% at 100 mm and RNAiDmSRS2 strain 23003 adults showed a reduction to 91.41 ± 1.62% at 20 mm, 72.31 ± 2.03% at 50 mm, 30.42 ± 3.91% at 100 mm (Figure 4C).
DmSRS2 depletion alters mitochondrial morphology and biogenesis
After the characterization of tissue and cellular defects caused by DmSRS2 silencing, we aimed to determine the effects at the subcellular level. Fat bodies from control larvae, or from the cross between actin5C-GAL4 and RNAiDmSRS2 strain 1-dcr2, at 29°C, were visualized by transmission electron microscopy (TEM). SRS2 silencing notably affected mitochondrial ultrastructure (Figure 5A) compared with control mitochondria. Mitochondria under DmSRS2 depletion were characterized by swollen matrices with low electron density, an evident reduction of cristae and a significant enlargement (Figure 5B), with an average mitochondrial surface of 0.920 ± 0.08 μm2, which represents a 66% increase relative to wt mitochondrial area (0.555 ± 0.05 μm2). >
To evaluate the effect on mitochondrial biogenesis of RNAiDmSRS expression, density of mitochondria was estimated by the quantification of relative mtDNA copy numbers. Larvae under DmSRS2 depletion showed an increase in mtDNA copy number (Figure 5C left panel). We observed a rise to 169.30 ± 8.61% when using RNAiDmSRS2 strain 1-dcr2 as parental line (at 29°C) and to 116.60 ± 4.39% when using strain 23003 (at 25°C). These results are in agreement with an increase in mitochondrial number observed in the electron micrographs, in which RNAiDmSRS2 affected adipocytes possessed 8.94 ± 0.73 mitochondria/100 μm2 of cell surface, compared with 7.01 ± 0.79 mitochondria/100 μm2 of cell surface in wild-type cells (Figure 5C right panel).
Mitochondrial translation deficiency leads to lactic acidosis and reduction of glycogen
One of the first signs of mitochondrial pathology in patients is the appearance of lactic acidosis, a physiological state caused by mitochondrial metabolism deficiency. Low levels of ATP synthesis result in the accumulation of cytosolic pyruvate, which is converted to lactate to satisfy energy demands (59). Simultaneously, inefficient mitochondrial respiration leads to the acidification of blood and tissues. Lactate concentration in samples from control flies had lactate values of 1.41 ± 0.11 nmol/μg protein, and 1.44 ± 0.11 nmol/μg protein, at 25 and 29°C, respectively (Figure 6A). In larval tissues under RNAiDmSRS2 activation, this concentration rose to 2.44 ± 0.27 nmol/μg protein and 2.7 ± 0.34 nmol/μg protein at 25 and 29°C, for strain 1-dcr2. Similarly, strain 23003 had lactate values of 2.53 ± 0.3 nmol/μg protein at 25°C. In agreement with these findings, the pH of DmSRS2-silenced larvae decreased from 7.19 ± 0.04 in w1118, to 7.05 ± 0.07 in RNAiDmSRS2 strain 1-dcr2, and to 7.07 ± 0.02 in strain 23003, at 25°C. Moreover, larvae maintained at 29°C showed a decrease in pH from 7.12 ± 0.04 to 6.70 ± 0.12 in RNAiDmSRS2 strain 1-dcr2 at 29°C (Figure 6B). >
Larval glycogen levels for control flies were also measured, obtaining a concentration of 0.82 ± 0.07 µg/µg protein at 25°C. The larval glycogen concentration at 25°C from strain 1-dcr2 and strain 23003 were 0.42 ± 0.06 µg/µg protein and 0.61 ± 0.04 µg/µg protein, respectively (Figure 6C, left panel). These results are in agreement with a reduction in the area occupied by glycogen observed in the electron micrographs (Figure 6C, right panel). Thus, the silencing of DmSRS2 leads to a statistically significant reduction in cellular glycogen.
Taken together, our results may indicate that an increase in lactate production and a reduction in stored glycogen are linked consequences of a decreased capacity for mitochondrial protein synthesis.
RNAiDmSRS2 compromises mitochondrial respiration and triggers ROS build-up
Because mitochondrial morphology, biogenesis and metabolism were altered in DmSRS2-silenced larvae, we decided to test if they were accompanied by a decrease in mitochondrial respiratory capacity. We monitored the mitochondrial oxygen consumption of larval tissues on addition of substrates and inhibitors of the respiratory chain and OXPHOS complexes (Figure 7A). Complex I RCR [oxygen consumption under ADP addition (GMD; state 3) divided by oxygen consumption limited by ADP (GM; state 2)] in larvae subjected to DmSRS2 general knockdown were lower than in control animals, indicating an uncoupling between the respiratory chain and OXPHOS (60). The RCR for RNAiDmSRS2 strain 1-dcr2 mitochondria showed a decrease to 2.45 ± 0.20, compared with control (3.10 ± 0.17) at 29°C and for RNAiDmSRS2 strain 23003 a reduction to 2.89 ± 0.07, in comparison with 3.95 ± 0.34 in w1118 at 25°C (Figure 7A, upper graphs). In larvae obtained from crosses between actin5C-GAL4 line and RNAiDmSRS2 strain 1-dcr2 (at 29°C) or strain 23003 (at 25°C), oxygen consumption values (normalized by mitochondrial density) showed a notable decrease, and thus the respiratory capacity per mitochondria is lower in RNAiDmSRS2 affected tissues (Figure 7A, lower graphs). The increment in mitochondrial surface and number might be a compensatory response to the limited mitochondrial function caused by the DmSRS2 depletion. >
To synthesize ATP by OXPHOS, the mitochondrial respiratory chain complexes transport electrons that are finally transferred to the molecular oxygen. When the respiratory chain and OXPHOS function incorrectly, ROS accumulate inside mitochondria and can induce oxidative stress. Taking into account that DmSRS2 is crucial for mitochondrial activity, we checked if the restricted expression of the RNAiDmSRS2 in the anteroposterior border of the wing imaginal disc (using patched-GAL4 driver) led to an increase in ROS. As shown in Figure 7B, wing imaginal discs exhibited a marked increase in superoxide anion restricted to cells under DmSRS2 interference at 29°C, comparable with that of cells affected by an RNAi against the ND75 complex I subunit of the respiratory chain, used as positive control.
Antioxidant treatment palliates defects caused by RNAiDmSRS2
Considering that reduction in mitochondrial tRNASer serylation disturbs organelle function and increases ROS production, we investigated whether supplementing flies’ diet with an antioxidant cocktail (K-PAX; K-PAX Inc.) may have a palliative effect on affected flies. Indeed, adult flies with muscle-specific RNAiDmSRS2 silencing at 29°C underwent a significant improvement in longevity (a half-life increase from 6 to 12 days) when treated with the antioxidant mix (Figure 8A). Similarly, supplementation with antioxidant molecules improved locomotion ability in both the RNAiDmSRS2 1-dcr2 and the RNAiDmSRS2 23003 strains (Figure 8B). In the case of RNAiDmSRS2 1-dcr2 adults, 96.45 ± 0.92% were able to pass the 20 mm mark (untreated 87.90 ± 4.79%), 88.03 ± 2.29% passed the 50 mm mark (untreated 75.22 ± 2.88%) and 70.24 ± 3.12% passed the 100 mm mark (untreated 60.27 ± 4.70%) (left panel). Among RNAiDmSRS2 strain 23003 flies, 96.26 ± 0.91% were able to pass the 20 mm mark (untreated 91.41 ± 1.62%), 80.17 ± 2.45% passed the 50 mm mark (untreated 72.31 ± 2.03%) and 40.15 ± 3.15 % passed the 100 mm mark (untreated 30.42 ± 3.91%) (right panel). >
DISCUSSION
As predicted, silencing of SRS2 expression by means of RNAi in D. melanogaster led to a decrease in the aminoacylation levels of the two mitochondrial tRNASer. This fact confirmed the DmSRS2 canonical function as mitochondrial seryl-tRNA synthetase in vivo [previously proposed by bioinformatic approaches in (44)], and allowed us to generate an animal model for human mitochondrial disease caused by aminoacylation deficiencies.
The stringency of the system was modulated using two different RNAi transgenic strains, crossing them with driver lines with various promoters and maintaining the animals at different temperatures. In that way, RNAiDmSRS2 strain 23003 resulted more efficient in targeting DmSRS2 mRNA and reducing serine-mt-tRNASer levels compared with RNAiDmSRS2 strain 1-dcr2 (Figure 2). Accordingly, the constitutive or tissue-restricted silencing using strain 23003 produced strongest consequences in adult viability, longevity and tissue development (Figures 3 and 4).
This approach allowed us to induce DmSRS2 silencing, and produce flies with different levels of protein depletion leading to a range of phenotype severity, which permitted a better reproduction of the variability of symptoms displayed by patients with mitochondrial disorders. This is particularly true of those symptoms caused by mutations in mt-tRNAs that cause MELAS or MERRF.
These pathologies are characterized by lactate acidosis and mitochondrial respiratory chain dysfunction (16–18,20,22,23), traits also present in our Drosophila model (Figures 6A, B and 7A). The drop in the complex I RCR, caused by an increase in the oxygen consumption in state 2, indicated an uncoupling between the respiratory chain and the OXPHOS, possibly due to an anomalous permeabilization of the mitochondrial inner membrane to protons, which could positively feedback the respiratory chain independently of the F1-F0-ATPase activity (60). Moreover, oxygen consumption values in the different respiratory states suffered a clear reduction when they were normalized taking into account the mitochondrial content (55). These results suggest that affected tissues in our model suffer from a defective mitochondrial respiratory capacity that is masked by an increase in mitochondrial biogenesis, a compensatory response also observed in patients with MELAS/MERRF symptoms (61–63). Intracellular ROS have been proposed as modulators of mitochondrial proliferation (64). Similarly, DmSRS2 deficiency might induce an increase in mitochondrial biogenesis stimulated by the accumulation in ROS (Figure 7C).
The mitochondria of MELAS and MERRF patients present varying degrees of heteroplasmy, that is, the coexistence of different proportions of wild-type and mutant mtDNA populations in different tissues. Pathological symptoms appear when the mutant mtDNA copy number exceeds the level that guarantees the correct functioning of a tissue (threshold effect), leading to a complex variety of clinical manifestations with different levels of severity. This situation is again mimicked by our model, whose mitochondria suffer from a partial ablation of DmSRS2 activity. The affected organelles appear enlarged, with a decrease in the surface occupied by cristae, and electron pale matrices (Figure 5). Apart from morphological abnormalities in mitochondria, the RNAiDmSRS2 prompted an increase in mitochondrial density, observed in the micrographs and confirmed by relative mtDNA quantification.
Taking into account the DmSRS2 silencing generated oxidative stress, and with the aim to asses a therapeutic approach to palliate the defects in longevity and locomotion ability caused by the muscular deficit of DmSRS2, antioxidants were added to flies’ diet and we observed an amelioration in both phenotypes (Figure 8). The commercial antioxidant mix used (K-PAX; K-PAX Inc.) is a complex combination of compounds, and thus it is difficult to discuss the beneficial effect observed in this work. However, the significant palliative effect observed warrants a deeper analysis on the potential therapeutic effect of ROS inhibitors in diseases caused by mitochondrial malfunction.
In support of this conclusion it should be noted that, during the preparation of this manuscript, a fly model for ataxia with leukoencephalopathy caused by rearrangements on methionyl-tRNA synthetase 2 gene was published (21). The phenotype observed in our model closely coincide with the model from Bayat et al., with the same kind of mitochondrial morphology and respiratory defects, as well as a build-up in mitochondrial biogenesis and ROS accumulation, and a reduction in cell proliferation independent of apoptosis and cell growth events.
Our animal model is able to reproduce many traits that characterize mitochondrial disorders caused by mutations in the mitochondrial serylation apparatus. As example, an insertion in the mt-tRNASer that cause sensorineural hearing loss, results in a reduction in serylation efficiency, a moderate mitochondrial dysfunction, morphological alterations and lactate elevation (65,66). Mutations in mt-tRNASer related to Multisystem Disease with Cataracts (67) and deafness, retinal degeneration, myopathy and epilepsy (68) cause defects in mitochondrial function, abnormal mitochondrial morphology and proliferation, and those involved in MELAS/MERRF result in a group of features, such as pleomorphic mitochondria, increment in lactate, decrease in respiratory chain activity and increase in mitochondrial density (69), that coincide with the phenotypes observed in our model. On the other hand, similar symptoms have also been observed in patients with HUPRA syndrome (hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis), which is caused by a mutation in the SRS2 gene (18).
The increasing number of pathogenic mutations found in mitochondrial aaRSs (15–23) justifies the generation of animal models for the study of these diseases and for the development of therapeutic strategies, among which treatment with antioxidant molecules should be considered.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online: Supplementary Figures 1–3 and Supplementary Methods.
FUNDING
Spanish Ministry of Economy and Innovation [BIO2012-32200]; PhD fellowship from the Government of Catalonia [FI-DGR 2011 to D.P.]. Funding for open access charge: Spanish Ministry of Economy and Innovation [BIO2013-09776].
Conflict of interest statement. None declared.
Supplementary Material
ACKNOWLEDGEMENTS
We are grateful to Dr Jordi Bernués (IBMB-CSIC) for his assistance and discussions on fly handling, Dr Jessica Segalés and Dr Antonio Zorzano (IRB) for the help provided and discussions regarding oxygen consumption experiments and to Anna Adrover and Isabel Sáez (IRB) for their assistance with metabolite determination assays. We thank Dr Andreu Casali (IBMB-CSIC/IRB) for providing fly stocks, Dr Jon D. Kaiser (K-PAX Inc) for supplying the antioxidant mixture used in this work and Dr Octavi Viñas for providing antibodies to detect mitochondrial proteins. We are grateful to Carmen López-Iglesias (Scientific and Technological Centers from the University of Barcelona) for her assistance in the electron microscopy preparations.
REFERENCES
- 1.Ibba M, Söll D. Aminoacyl-tRNA synthesis. Annu. Rev. Biochem. 2000;69:617–650. doi: 10.1146/annurev.biochem.69.1.617. [DOI] [PubMed] [Google Scholar]
- 2.Ruiz-Pesini E, Lott MT, Procaccio V, Poole JC, Brandon MC, Mishmar D, Yi C, Kreuziger J, Baldi P, Wallace DC. An enhanced MITOMAP with a global mtDNA mutational phylogeny. Nucleic Acids Res. 2007;35:D823–D828. doi: 10.1093/nar/gkl927. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Goto Y, Nonaka I, Horai S. A mutation in the tRNA(Leu)(UUR) gene associated with the MELAS subgroup of mitochondrial encephalomyopathies. Nature. 1990;348:651–653. doi: 10.1038/348651a0. [DOI] [PubMed] [Google Scholar]
- 4.Kobayashi Y, Momoi MY, Tominaga K, Momoi T, Nihei K, Yanagisawa M, Kagawa Y, Ohta S. A point mutation in the mitochondrial tRNA(Leu)(UUR) gene in MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) Biochem. Biophys. Res. Commun. 1990;173:816–822. doi: 10.1016/s0006-291x(05)80860-5. [DOI] [PubMed] [Google Scholar]
- 5.Shoffner JM, Lott MT, Lezza AM, Seibel P, Ballinger SW, Wallace DC. Myoclonic epilepsy and ragged-red fiber disease (MERRF) is associated with a mitochondrial DNA tRNA(Lys) mutation. Cell. 1990;61:931–937. doi: 10.1016/0092-8674(90)90059-n. [DOI] [PubMed] [Google Scholar]
- 6.Reid FM, Vernham GA, Jacobs HT. A novel mitochondrial point mutation in a maternal pedigree with sensorineural deafness. Hum. Mutat. 1994;3:243–247. doi: 10.1002/humu.1380030311. [DOI] [PubMed] [Google Scholar]
- 7.Scheper GC, van der Knaap MS, Proud CG. Translation matters: protein synthesis defects in inherited disease. Nat. Rev. Genet. 2007;8:711–723. doi: 10.1038/nrg2142. [DOI] [PubMed] [Google Scholar]
- 8.Antonellis A, Ellsworth RE, Sambuughin N, Puls I, Abel A, Lee-Lin SQ, Jordanova A, Kremensky I, Christodoulou K, Middleton LT, et al. Glycyl tRNA synthetase mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. Am. J. Hum. Genet. 2003;72:1293–1299. doi: 10.1086/375039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Jordanova A, Irobi J, Thomas FP, Van Dijck P, Meerschaert K, Dewil M, Dierick I, Jacobs A, De Vriendt E, Guergueltcheva V, et al. Disrupted function and axonal distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth neuropathy. Nat. Genet. 2006;38:197–202. doi: 10.1038/ng1727. [DOI] [PubMed] [Google Scholar]
- 10.Latour P, Thauvin-Robinet C, Baudelet-Mery C, Soichot P, Cusin V, Faivre L, Locatelli MC, Mayencon M, Sarcey A, Broussolle E, et al. A major determinant for binding and aminoacylation of tRNA(Ala) in cytoplasmic Alanyl-tRNA synthetase is mutated in dominant axonal Charcot-Marie-Tooth disease. Am. J. Hum. Genet. 2010;86:77–82. doi: 10.1016/j.ajhg.2009.12.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.McLaughlin HM, Sakaguchi R, Liu C, Igarashi T, Pehlivan D, Chu K, Iyer R, Cruz P, Cherukuri PF, Hansen NF, et al. Compound heterozygosity for loss-of-function lysyl-tRNA synthetase mutations in a patient with peripheral neuropathy. Am. J. Hum. Genet. 2010;87:560–566. doi: 10.1016/j.ajhg.2010.09.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.He W, Zhang HM, Chong YE, Guo M, Marshall AG, Yang XL. Dispersed disease-causing neomorphic mutations on a single protein promote the same localized conformational opening. Proc. Natl Acad. Sci. USA. 2011;108:12307–12312. doi: 10.1073/pnas.1104293108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Froelich CA, First EA. Dominant Intermediate Charcot-Marie-Tooth disorder is not due to a catalytic defect in tyrosyl-tRNA synthetase. Biochemistry. 2011;50:7132–7145. doi: 10.1021/bi200989h. [DOI] [PubMed] [Google Scholar]
- 14.Motley WW, Seburn KL, Nawaz MH, Miers KE, Cheng J, Antonellis A, Green ED, Talbot K, Yang XL, Fischbeck KH, et al. Charcot-Marie-Tooth-linked mutant GARS is toxic to peripheral neurons independent of wild-type GARS levels. PLoS Genet. 2011;7:e1002399. doi: 10.1371/journal.pgen.1002399. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Scheper GC, van der Klok T, van Andel RJ, van Berkel CG, Sissler M, Smet J, Muravina TI, Serkov SV, Uziel G, Bugiani M, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat. Genet. 2007;39:534–539. doi: 10.1038/ng2013. [DOI] [PubMed] [Google Scholar]
- 16.Edvardson S, Shaag A, Kolesnikova O, Gomori JM, Tarassov I, Einbinder T, Saada A, Elpeleg O. Deleterious mutation in the mitochondrial arginyl-transfer RNA synthetase gene is associated with pontocerebellar hypoplasia. Am. J. Hum. Genet. 2007;81:857–862. doi: 10.1086/521227. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Riley LG, Cooper S, Hickey P, Rudinger-Thirion J, McKenzie M, Compton A, Lim SC, Thorburn D, Ryan MT, Giege R, et al. Mutation of the mitochondrial tyrosyl-tRNA synthetase gene, YARS2, causes myopathy, lactic acidosis, and sideroblastic anemia—MLASA syndrome. Am. J. Hum. Genet. 2010;87:52–59. doi: 10.1016/j.ajhg.2010.06.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Belostotsky R, Ben-Shalom E, Rinat C, Becker-Cohen R, Feinstein S, Zeligson S, Segel R, Elpeleg O, Nassar S, Frishberg Y. Mutations in the mitochondrial seryl-tRNA synthetase cause hyperuricemia, pulmonary hypertension, renal failure in infancy and alkalosis, HUPRA syndrome. Am. J. Hum. Genet. 2011;88:193–200. doi: 10.1016/j.ajhg.2010.12.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Pierce SB, Chisholm KM, Lynch ED, Lee MK, Walsh T, Opitz JM, Li W, Klevit RE, King MC. Mutations in mitochondrial histidyl tRNA synthetase HARS2 cause ovarian dysgenesis and sensorineural hearing loss of Perrault syndrome. Proc. Natl Acad. Sci. USA. 2011;108:6543–6548. doi: 10.1073/pnas.1103471108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Götz A, Tyynismaa H, Euro L, Ellonen P, Hyotylainen T, Ojala T, Hamalainen RH, Tommiska J, Raivio T, Oresic M, et al. Exome sequencing identifies mitochondrial alanyl-tRNA synthetase mutations in infantile mitochondrial cardiomyopathy. Am. J. Hum. Genet. 2011;88:635–642. doi: 10.1016/j.ajhg.2011.04.006. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Bayat V, Thiffault I, Jaiswal M, Tetreault M, Donti T, Sasarman F, Bernard G, Demers-Lamarche J, Dicaire MJ, Mathieu J, et al. Mutations in the mitochondrial methionyl-tRNA synthetase cause a neurodegenerative phenotype in flies and a recessive ataxia (ARSAL) in humans. PLoS Biol. 2012;10:e1001288. doi: 10.1371/journal.pbio.1001288. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Steenweg ME, Ghezzi D, Haack T, Abbink TE, Martinelli D, van Berkel CG, Bley A, Diogo L, Grillo E, Te Water Naude J, et al. Leukoencephalopathy with thalamus and brainstem involvement and high lactate ‘LTBL' caused by EARS2 mutations. Brain. 2012;135:1387–1394. doi: 10.1093/brain/aws070. [DOI] [PubMed] [Google Scholar]
- 23.Elo JM, Yadavalli SS, Euro L, Isohanni P, Gotz A, Carroll CJ, Valanne L, Alkuraya FS, Uusimaa J, Paetau A, et al. Mitochondrial phenylalanyl-tRNA synthetase mutations underlie fatal infantile Alpers encephalopathy. Hum. Mol. Genet. 2012;21:4521–4529. doi: 10.1093/hmg/dds294. [DOI] [PubMed] [Google Scholar]
- 24.Seburn KL, Nangle LA, Cox GA, Schimmel P, Burgess RW. An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. Neuron. 2006;51:715–726. doi: 10.1016/j.neuron.2006.08.027. [DOI] [PubMed] [Google Scholar]
- 25.Chihara T, Luginbuhl D, Luo L. Cytoplasmic and mitochondrial protein translation in axonal and dendritic terminal arborization. Nat. Neurosci. 2007;10:828–837. doi: 10.1038/nn1910. [DOI] [PubMed] [Google Scholar]
- 26.Achilli F, Bros-Facer V, Williams HP, Banks GT, AlQatari M, Chia R, Tucci V, Groves M, Nickols CD, Seburn KL, et al. An ENU-induced mutation in mouse glycyl-tRNA synthetase (GARS) causes peripheral sensory and motor phenotypes creating a model of Charcot-Marie-Tooth type 2D peripheral neuropathy. Dis. Model. Mech. 2009;2:359–373. doi: 10.1242/dmm.002527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Storkebaum E, Leitao-Goncalves R, Godenschwege T, Nangle L, Mejia M, Bosmans I, Ooms T, Jacobs A, Van Dijck P, Yang XL, et al. Dominant mutations in the tyrosyl-tRNA synthetase gene recapitulate in Drosophila features of human Charcot-Marie-Tooth neuropathy. Proc. Natl Acad. Sci. USA. 2009;106:11782–11787. doi: 10.1073/pnas.0905339106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Butow RA, Henke RM, Moran JV, Belcher SM, Perlman PS. Transformation of Saccharomyces cerevisiae mitochondria using the biolistic gun. Methods Enzymol. 1996;264:265–278. doi: 10.1016/s0076-6879(96)64026-9. [DOI] [PubMed] [Google Scholar]
- 29.Bonnefoy N, Fox TD. Genetic transformation of Saccharomyces cerevisiae mitochondria. Methods Cell Biol. 2001;65:381–396. doi: 10.1016/s0091-679x(01)65022-2. [DOI] [PubMed] [Google Scholar]
- 30.Feuermann M, Francisci S, Rinaldi T, De Luca C, Rohou H, Frontali L, Bolotin-Fukuhara M. The yeast counterparts of human ‘MELAS' mutations cause mitochondrial dysfunction that can be rescued by overexpression of the mitochondrial translation factor EF-Tu. EMBO Rep. 2003;4:53–58. doi: 10.1038/sj.embor.embor713. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.King MP, Attardi G. Human cells lacking mtDNA: repopulation with exogenous mitochondria by complementation. Science. 1989;246:500–503. doi: 10.1126/science.2814477. [DOI] [PubMed] [Google Scholar]
- 32.Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J. Neurosci. Res. 2007;85:3416–3428. doi: 10.1002/jnr.21167. [DOI] [PubMed] [Google Scholar]
- 33.Toivonen JM, O'Dell KM, Petit N, Irvine SC, Knight GK, Lehtonen M, Longmuir M, Luoto K, Touraille S, Wang Z, et al. Technical knockout, a Drosophila model of mitochondrial deafness. Genetics. 2001;159:241–254. doi: 10.1093/genetics/159.1.241. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kolesnikova OA, Entelis NS, Jacquin-Becker C, Goltzene F, Chrzanowska-Lightowlers ZM, Lightowlers RN, Martin RP, Tarassov I. Nuclear DNA-encoded tRNAs targeted into mitochondria can rescue a mitochondrial DNA mutation associated with the MERRF syndrome in cultured human cells. Hum. Mol. Genet. 2004;13:2519–2534. doi: 10.1093/hmg/ddh267. [DOI] [PubMed] [Google Scholar]
- 35.Mahata B, Mukherjee S, Mishra S, Bandyopadhyay A, Adhya S. Functional delivery of a cytosolic tRNA into mutant mitochondria of human cells. Science. 2006;314:471–474. doi: 10.1126/science.1129754. [DOI] [PubMed] [Google Scholar]
- 36.Karicheva OZ, Kolesnikova OA, Schirtz T, Vysokikh MY, Mager-Heckel AM, Lombes A, Boucheham A, Krasheninnikov IA, Martin RP, Entelis N, et al. Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. Nucleic Acids Res. 2011;39:8173–8186. doi: 10.1093/nar/gkr546. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Wang G, Shimada E, Zhang J, Hong JS, Smith GM, Teitell MA, Koehler CM. Correcting human mitochondrial mutations with targeted RNA import. Proc. Natl Acad. Sci. USA. 2012;109:4840–4845. doi: 10.1073/pnas.1116792109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Park H, Davidson E, King MP. Overexpressed mitochondrial leucyl-tRNA synthetase suppresses the A3243G mutation in the mitochondrial tRNA(Leu(UUR)) gene. RNA. 2008;14:2407–2416. doi: 10.1261/rna.1208808. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Li R, Guan MX. Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunctions due to the tRNALeu(UUR) A3243G mutation, associated with mitochondrial encephalomyopathy, lactic acidosis, and stroke-like symptoms and diabetes. Mol. Cell. Biol. 2010;30:2147–2154. doi: 10.1128/MCB.01614-09. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Marchington DR, Barlow D, Poulton J. Transmitochondrial mice carrying resistance to chloramphenicol on mitochondrial DNA: developing the first mouse model of mitochondrial DNA disease. Nat. Med. 1999;5:957–960. doi: 10.1038/11403. [DOI] [PubMed] [Google Scholar]
- 41.Sligh JE, Levy SE, Waymire KG, Allard P, Dillehay DL, Nusinowitz S, Heckenlively JR, MacGregor GR, Wallace DC. Maternal germ-line transmission of mutant mtDNAs from embryonic stem cell-derived chimeric mice. Proc. Natl Acad. Sci. USA. 2000;97:14461–14466. doi: 10.1073/pnas.250491597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Inoue K, Nakada K, Ogura A, Isobe K, Goto Y, Nonaka I, Hayashi JI. Generation of mice with mitochondrial dysfunction by introducing mouse mtDNA carrying a deletion into zygotes. Nat. Genet. 2000;26:176–181. doi: 10.1038/82826. [DOI] [PubMed] [Google Scholar]
- 43.Li J, Zhou K, Meng X, Wu Q, Li S, Liu Y, Wang J. Increased ROS generation and SOD activity in heteroplasmic tissues of transmitochondrial mice with A3243G mitochondrial DNA mutation. Genet. Mol. Res. 2008;7:1054–1062. doi: 10.4238/vol7-4gmr480. [DOI] [PubMed] [Google Scholar]
- 44.Guitart T, Leon Bernardo T, Sagales J, Stratmann T, Bernues J, Ribas de Pouplana L. New aminoacyl-tRNA synthetase-like protein in insecta with an essential mitochondrial function. J. Biol. Chem. 2010;285:38157–38166. doi: 10.1074/jbc.M110.167486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Lee YS, Carthew RW. Making a better RNAi vector for Drosophila: use of intron spacers. Methods. 2003;30:322–329. doi: 10.1016/s1046-2023(03)00051-3. [DOI] [PubMed] [Google Scholar]
- 46.Rubin GM, Spradling AC. Genetic transformation of Drosophila with transposable element vectors. Science. 1982;218:348–353. doi: 10.1126/science.6289436. [DOI] [PubMed] [Google Scholar]
- 47.Dietzl G, Chen D, Schnorrer F, Su KC, Barinova Y, Fellner M, Gasser B, Kinsey K, Oppel S, Scheiblauer S, et al. A genome-wide transgenic RNAi library for conditional gene inactivation in Drosophila. Nature. 2007;448:151–156. doi: 10.1038/nature05954. [DOI] [PubMed] [Google Scholar]
- 48.Brand AH, Perrimon N. Targeted gene expression as a means of altering cell fates and generating dominant phenotypes. Development. 1993;118:401–415. doi: 10.1242/dev.118.2.401. [DOI] [PubMed] [Google Scholar]
- 49.Saini N, Georgiev O, Schaffner W. The parkin mutant phenotype in the fly is largely rescued by metal-responsive transcription factor (MTF-1) Mol. Cell. Biol. 2011;31:2151–2161. doi: 10.1128/MCB.05207-11. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Walker SE, Fredrick K. Preparation and evaluation of acylated tRNAs. Methods. 2008;44:81–86. doi: 10.1016/j.ymeth.2007.09.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Wilhelm ML, Baranowski W, Keith G, Wilhelm FX. Rapid transfer of small RNAs from a polyacrylamide gel onto a nylon membrane using a gel dryer. Nucleic Acids Res. 1992;20:4106. doi: 10.1093/nar/20.15.4106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Abramoff MD, Magelhaes PJ, Ram SJ. Image processing with imageJ. Biophotonics Int. 2004;11:36–42. [Google Scholar]
- 53.Gutmann I, Wahlefel AW. Methods of Enzymatic Analysis (Bergmeyer H. U.) New York, NY, USA: Academic Press, Inc; 1974. [Google Scholar]
- 54.Zhu A, Romero R, Petty HR. An enzymatic fluorimetric assay for glucose-6-phosphate: application in an in vitro Warburg-like effect. Anal. Biochem. 2009;388:97–101. doi: 10.1016/j.ab.2009.02.009. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Boushel R, Gnaiger E, Schjerling P, Skovbro M, Kraunsoe R, Dela F. Patients with type 2 diabetes have normal mitochondrial function in skeletal muscle. Diabetologia. 2007;50:790–796. doi: 10.1007/s00125-007-0594-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Owusu-Ansah E, Yavari A, Banerjee U. A protocol for in vivo detection of reactive oxygen species. Nat. Protoc. 2008 27 February (doi:10.1038/nprot.2008.23; epub ahead of print) [Google Scholar]
- 57.Duffy JB. GAL4 system in Drosophila: a fly geneticist's Swiss army knife. Genesis. 2002;34:1–15. doi: 10.1002/gene.10150. [DOI] [PubMed] [Google Scholar]
- 58.Phillips RG, Roberts IJ, Ingham PW, Whittle JR. The Drosophila segment polarity gene patched is involved in a position-signalling mechanism in imaginal discs. Development. 1990;110:105–114. doi: 10.1242/dev.110.1.105. [DOI] [PubMed] [Google Scholar]
- 59.Ogasawara E, Nakada K, Hayashi J. Lactic acidemia in the pathogenesis of mice carrying mitochondrial DNA with a deletion. Hum. Mol. Genet. 2010;19:3179–3189. doi: 10.1093/hmg/ddq228. [DOI] [PubMed] [Google Scholar]
- 60.Gnaiger E. MitoPathways: Respiratory States ant Coupling Control Ratios. 2011. OROBOROS Mitochondrial Physiology Network Publications, Innsbruck. [Google Scholar]
- 61.Mita S, Tokunaga M, Kumamoto T, Uchino M, Nonaka I, Ando M. Mitochondrial DNA mutation and muscle pathology in mitochondrial myopathy, encephalopathy, lactic acidosis, and strokelike episodes. Muscle Nerve. 1995;3:S113–S118. doi: 10.1002/mus.880181423. [DOI] [PubMed] [Google Scholar]
- 62.Oldfors A, Holme E, Tulinius M, Larsson NG. Tissue distribution and disease manifestations of the tRNA(Lys) A—>G(8344) mitochondrial DNA mutation in a case of myoclonus epilepsy and ragged red fibres. Acta Neuropathol. 1995;90:328–333. doi: 10.1007/BF00296519. [DOI] [PubMed] [Google Scholar]
- 63.Melone MA, Tessa A, Petrini S, Lus G, Sampaolo S, di Fede G, Santorelli FM, Cotrufo R. Revelation of a new mitochondrial DNA mutation (G12147A) in a MELAS/MERRF phenotype. Arch. Neurol. 2004;61:269–272. doi: 10.1001/archneur.61.2.269. [DOI] [PubMed] [Google Scholar]
- 64.Lee HC, Wei YH. Mitochondrial biogenesis and mitochondrial DNA maintenance of mammalian cells under oxidative stress. Int. J. Biochem. Cell Biol. 2005;37:822–834. doi: 10.1016/j.biocel.2004.09.010. [DOI] [PubMed] [Google Scholar]
- 65.Toompuu M, Yasukawa T, Suzuki T, Hakkinen T, Spelbrink JN, Watanabe K, Jacobs HT. The 7472insC mitochondrial DNA mutation impairs the synthesis and extent of aminoacylation of tRNASer(UCN) but not its structure or rate of turnover. J. Biol. Chem. 2002;277:22240–22250. doi: 10.1074/jbc.M200338200. [DOI] [PubMed] [Google Scholar]
- 66.Cardaioli E, Da Pozzo P, Cerase A, Sicurelli F, Malandrini A, De Stefano N, Stromillo ML, Battisti C, Dotti MT, Federico A. Rapidly progressive neurodegeneration in a case with the 7472insC mutation and the A7472C polymorphism in the mtDNA tRNASer(UCN) gene. Neuromuscul. Disord. 2006;16:26–31. doi: 10.1016/j.nmd.2005.11.001. [DOI] [PubMed] [Google Scholar]
- 67.Schrier SA, Wong LJ, Place E, Ji JQ, Pierce EA, Golden J, Santi M, Anninger W, Falk MJ. Mitochondrial tRNA-serine (AGY) m.C12264T mutation causes severe multisystem disease with cataracts. Discov. Med. 2012;13:143–150. [PMC free article] [PubMed] [Google Scholar]
- 68.Tuppen HA, Naess K, Kennaway NG, Al-Dosary M, Lesko N, Yarham JW, Bruhn H, Wibom R, Nennesmo I, Weleber RG, et al. Mutations in the mitochondrial tRNA(Ser(AGY)) gene are associated with deafness, retinal degeneration, myopathy and epilepsy. Eur. J. Hum. Genet. 2012;20:897–904. doi: 10.1038/ejhg.2012.44. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69.Wong LJ, Yim D, Bai RK, Kwon H, Vacek MM, Zane J, Hoppel CL, Kerr DS. A novel mutation in the mitochondrial tRNA(Ser(AGY)) gene associated with mitochondrial myopathy, encephalopathy, and complex I deficiency. J. Med. Genet. 2006;43:e46. doi: 10.1136/jmg.2005.040626. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.